THRB and metabolic dysfunction-associated steatohepatitis: Tissue-specific SNRMs, such as liver-targeted THR-β agonists like resmetirom, promote hepatic fat oxidation and show promise in treating MASH by reducing liver fat content without affecting other tissues.